Patents by Inventor Ralph Minter

Ralph Minter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10370436
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 6, 2019
    Assignee: MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Patent number: 10329345
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: June 25, 2019
    Assignee: MedImmune Limited
    Inventors: Vahe Bedian, William Dall'Acqua, Herren Wu, Michael Bowen, Jeffrey Brown, Ralph Minter, Andrew Buchanan
  • Patent number: 10287362
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 14, 2019
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20180273616
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 27, 2018
    Inventors: Elaine M. HURT, Ralph MINTER, Steven RUST, Alan SANDERCOCK, Sotirios KARATHANASIS
  • Publication number: 20180208639
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 26, 2018
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Publication number: 20180194858
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 12, 2018
    Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
  • Patent number: 9938356
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: April 10, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Patent number: 9884902
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 6, 2018
    Assignee: MedImmune Limited
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Publication number: 20170226158
    Abstract: The disclosure generally provides a Designed Ankyrin Repeat Protein (DARPin) that specifically binds to an antigen, the DARPin having an N-terminal cap section, at least two Ankyrin Repeat (AR) module sections, and a C-terminal cap section, characterized in that the DARPin has a charge that is less negative than known 5 DARPins. The disclosure also provides for generation of a library of the less negative DARPins.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 10, 2017
    Inventors: Ralph MINTER, Ron JACKSON, Lasse KJELLERUP
  • Publication number: 20170183397
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV bispecific binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: May 4, 2015
    Publication date: June 29, 2017
    Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
  • Publication number: 20170174756
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Application
    Filed: October 27, 2016
    Publication date: June 22, 2017
    Inventors: VAHE BEDIAN, William DALL'ACQUA, Herren WU, Michael BOWEN, Jeffrey BROWN, Ralph MINTER, Andrew BUCHANAN
  • Publication number: 20170114151
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Application
    Filed: August 8, 2016
    Publication date: April 27, 2017
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • Patent number: 9580509
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: February 28, 2017
    Assignee: MedImmune, LLC
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • Publication number: 20160297872
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Application
    Filed: June 24, 2016
    Publication date: October 13, 2016
    Inventors: Antonio DiGiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Patent number: 9403901
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 2, 2016
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Publication number: 20160194407
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Inventors: Carl HAY, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20150284450
    Abstract: The disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: November 6, 2013
    Publication date: October 8, 2015
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao
  • Publication number: 20150104450
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: March 11, 2013
    Publication date: April 16, 2015
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Publication number: 20150023966
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: November 6, 2012
    Publication date: January 22, 2015
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, SAndrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainney, Cuihua GAO
  • Publication number: 20140227285
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Application
    Filed: June 8, 2012
    Publication date: August 14, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Gullard, Ralph Minter, Steven Rust, Mladen Tomich